BioCentury | Dec 22, 2017
Clinical News

FDA approves Aclaris' Eskata to treat SK

Aclaris Therapeutics Inc. (NASDAQ:ACRS) said FDA approved Eskata hydrogen peroxide topical solution 40% to treat raised seborrheic keratosis (SK). Aclaris plans to launch Eskata in the U.S. in spring 2018. It will be available as...
BioCentury | Oct 6, 2017

Coasting on catalysts

While buysiders do not expect any sector-moving milestones in the wake of a catalyst-heavy third quarter, they will have at least 21 Phase III milestones and 23 PDUFA dates on their radar. But the biggest...
BioCentury | Sep 8, 2017
Clinical News

Aclaris submits MAA for dermatology candidate A-101

Aclaris Therapeutics Inc. (NASDAQ:ACRS) submitted an MAA under the EU decentralized procedure, with Sweden as the reference member state, for A-101 to treat seborrheic keratosis (SK). An NDA for A-101 is under FDA review with...
BioCentury | Aug 18, 2017
Financial News

Aclaris prices $75M follow-on

On Aug. 10, Aclaris Therapeutics Inc. (NASDAQ:ACRS) raised $75 million through the sale of 3.3 million shares in a follow-on underwritten by Jefferies, Leerink, William Blair, Guggenheim and JMP Securities. Aclaris’ lead asset, A-101 , is...
BioCentury | Aug 11, 2017
Financial News

Aclaris, Kura price follow-ons

Dermatology play Aclaris Therapeutics Inc. (NASDAQ:ACRS) and cancer company Kura Oncology Inc. (NASDAQ:KURA) both priced follow-ons late Thursday, raising over $125 million total. Aclaris raised $75 million though the sale of 3.3 million shares at...
BioCentury | Jul 8, 2017

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...
BioCentury | May 12, 2017
Clinical News

FDA accepts NDA for seborrheic keratosis candidate A-101

FDA accepted for review an NDA from Aclaris Therapeutics Inc. (NASDAQ:ACRS) for A-101 to treat seborrheic keratosis (SK). The PDUFA date is Dec. 24. In the Phase III SEBK-301 and SEBK-302 trials, the high-concentration hydrogen...
BioCentury | Apr 7, 2017

To market, to market

Investors are hoping that a slew of approvals and data readouts can maintain biotech’s momentum on the heels of several high-profile successes that came just before or after 1Q’s end. Chief among those was Vertex...
BioCentury | Mar 2, 2017
Clinical News

A-101 regulatory update

Aclaris submitted an NDA to FDA for A-101 to treat seborrheic keratosis (SK). The submission is supported by data from the double-blind, vehicle-controlled, U.S. Phase III SEBK-301 and SEB-302 trials showing that A-101 led to...
BioCentury | Dec 31, 2016

Delivering takeouts

BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are looking...
Items per page:
1 - 10 of 30